Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems.
Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
On August 11, 2023, Novartis completed its acquisition of Chinook Therapeutics. For more information, please visit the Novartis Investors and Novartis News pages.
June 17, 2023
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
Data Provided by Refinitiv. Minimum 15 minutes delayed.